The development and clinical use of trastuzumab (Herceptin).

The Hallmarks of Cancer

2000 • 27,569 citations

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

1987 • 11,429 citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

2001 • 11,070 citations

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer

1989 • 6,734 citations

Untangling the ErbB signalling network

2001 • 6,623 citations

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

2002 • 2,968 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

1999 • 2,747 citations

Humanization of an anti-p185HER2 antibody for human cancer therapy.

1992 • 1,867 citations

Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene

1985 • 1,804 citations

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

1996 • 1,393 citations

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1984 • 1,153 citations

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

1998 • 1,086 citations

Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial

2001 • 1,075 citations

Amplification of a Novel v- erb B-Related Gene in a Human Mammary Carcinoma

1985 • 1,064 citations

Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts.

1998 • 1,013 citations

The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

1998 • 973 citations

2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

2001 • 882 citations

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1992 • 855 citations

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.

1997 • 841 citations

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

1997 • 811 citations

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

1981 • 795 citations

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1999 • 687 citations

p185^HER2 Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor

1989 • 672 citations

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

1999 • 650 citations

A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma.

1985 • 607 citations

Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.

1996 • 564 citations

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group.

1993 • 517 citations

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

1989 • 479 citations

Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.

1994 • 439 citations

Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.

1990 • 401 citations

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1998 • 380 citations

Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer

2001 • 377 citations

Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.

1999 • 309 citations

HER-2/neu (c-erb-B2) gene and protein in breast cancer.

1999 • 285 citations

Trastuzumab and chemotherapeutics: drug interactions and synergies.

2000 • 171 citations

Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.

1991 • 163 citations

Retrospective Analysis of the Safety of Herceptin<sup>®</sup> Immunotherapy in Metastatic Breast Cancer

2001 • 156 citations

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

2023 • 146 citations

Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?

1992 • 131 citations

Radiolabeled antibody targeting of the HER-2/neu oncoprotein.

1992 • 119 citations

Receptor blockade with monoclomal antibodies as anti-cancer therapy

1994 • 96 citations

Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity.

2000 • 75 citations

HER2

2000 • 51 citations

Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer

2001 • 45 citations

HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer

2001 • 21 citations

A phase II multicenter trial of weekly herceptin with navelbine in chemonaive patients with her2 positive metastatic breast cancer

2001 • 7 citations

Effect of cardiac dysfunction on treatment outcome in the Herceptin (trastuzumab) pivotal trial

2001 • 3 citations

Deleted Work

1955 • 0 citations